Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 9/20 | 0.54 |
| ▸ | GRM5 | P41594 | 8/20 | 0.54 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850634 | 0.90 | GRM1 (0.44) | GRM1GRM5CDK9NAMPTCNR1 | |
| SCHEMBL4847387 | 0.83 | GRM1 (0.50) | GRM1GRM5CDK9CCNT1NAMPT | |
| SCHEMBL2594283 | 0.83 | GRM1 (0.65) | GRM1GRM5CDK9CCNT1NAMPT | |
| SCHEMBL4850819 | 0.81 | TNK2 (0.46) | GRM1GRM5CDK9NAMPTCNR1 | |
| SCHEMBL7838136 | 0.76 | GRM5 (0.55) | GRM1GRM5NAMPTCNR1PDK4 | |
| SCHEMBL652961 | 0.76 | NAMPT (0.60) | GRM1GRM5NAMPTCNR1ENPP2 | |
| SCHEMBL949070 | 0.76 | GRM1 (0.48) | GRM1GRM5CDK9CCNT1NAMPT | |
| SCHEMBL14545550 | 0.75 | GRM1 (0.60) | GRM1GRM5NAMPTENPP2KIT | |
| SCHEMBL17645656 | 0.75 | CDK9 (0.49) | GRM1GRM5CDK9CCNT1NAMPT | |
| SCHEMBL3706064 | 0.75 | GRM1 (0.55) | GRM1GRM5CDK9CCNT1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | GRM1 627/4885GRM5 607/4885CDK9 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.